Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-041349
Filing Date
2023-08-10
Accepted
2023-08-10 16:16:58
Documents
73
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q elvn-20230630.htm   iXBRL 10-Q 3291569
2 EX-31.1 elvn-ex31_1.htm EX-31.1 18353
3 EX-31.2 elvn-ex31_2.htm EX-31.2 18355
4 EX-32.1 elvn-ex32_1.htm EX-32.1 11330
5 EX-32.2 elvn-ex32_2.htm EX-32.2 11320
6 GRAPHIC img251746512_0.jpg GRAPHIC 28618
  Complete submission text file 0000950170-23-041349.txt   10224238

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT elvn-20230630_cal.xml EX-101.CAL 39711
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT elvn-20230630_lab.xml EX-101.LAB 468872
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT elvn-20230630_def.xml EX-101.DEF 212409
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT elvn-20230630_pre.xml EX-101.PRE 349516
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT elvn-20230630.xsd EX-101.SCH 61207
67 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20230630_htm.xml XML 1736407
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39247 | Film No.: 231159723
SIC: 2834 Pharmaceutical Preparations